-
Mashup Score: 1
PRNEWS looked at announcements made this week by TikTok, the publishing industry and Eli Lilly, hoping to improve the lives of those impacted.
Source: PRNEWSCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0
This decision was based from the analysis of the company’s phase 2 BLAZE-4 trial.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
This #FDA decision was based from the analysis of the company's phase 2 BLAZE-4 trial. #Lilly #monoclonalantibodies https://t.co/K4Fsksnaa6
-
-
Mashup Score: 0
Results from two phase 3 trials evaluating tirzepatide in adults with type 2 diabetes showed statistically significant HbA1c and body weight reductions.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Investigational diabetes treatment shows significant reductions in HbA1c and weight compared to titrated insulin degludec. #T2D #Lilly https://t.co/5Pah6uzI80
-
-
Mashup Score: 1
Results from two phase 3 trials evaluating tirzepatide in adults with type 2 diabetes showed statistically significant HbA1c and body weight reductions.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Investigational new diabetes treatment shows significant reductions in HbA1c and weight compared to titrated insulin degludec. #T2D #Lilly https://t.co/ZQoXARcTSd
-
-
Mashup Score: 3FDA approves emergency use of antibody to treat COVID-19 - 4 year(s) ago
Dr. Marc Siegel weighs in on ‘America’s Newsroom.’
Source: Fox NewsCategories: Healthcare Professionals, Latest HeadlinesTweet-
FDA approves emergency use of antibody to treat COVID-19 https://t.co/rtdspAKqoB #LILLY #antibodies #Covid_19 #pandemic @AmericaNewsroom @SandraSmithFox
-
-
Mashup Score: 606
U.S. government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesn’t…
Source: MarketWatchCategories: Hem/Oncs, Latest HeadlinesTweet-
Just now: No more hospitalized patients will receive #Lilly Antibody bamlanivimab to #COVID19 as it “is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease." https://t.co/mL07E1pJyL
-
-
Mashup Score: 0FDA Panel Votes on Ramucirumab for First-Line Treatment of Metastatic EGFR-Positive NSCLC - MPR - 4 year(s) ago
The Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee voted 6 to 5 that ramucirumab (Cyramza; Lilly) plus erlotinib demonstrated a favorable benefit/risk profile for patients with untreated metastatic epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). The vote was based on data from the phase 3 RELAY study (N=449), which evaluated…
Source: MPRCategories: General Medicine Journals and SocietiesTweet-
The FDA's panel voted 6 to 5 that ramucirumab (Cyramza) plus erlotinib demonstrated a favorable benefit/risk profile in metastatic EGFR-Positive NSCLC #Lilly #NSCLC https://t.co/9cnZn7nZtl
-
GREAT READ: @PRNews Roundup: #TikTok Screen Time, #Dilbert Done, #EliLilly's #Reputation by @Buffalogal. Hear my thoughts on the #Lilly #diabetes pricing included in Nicole's reputation roundup. #pharmapricing #PBMs #Medicare #Access https://t.co/oi2Fd9B9Kc